Credit Suisse’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Credit Suisse’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-486,872	Closed	-$23.4M	–	4295
2020 Q1	$23.4M	Buy	486,872 +131,782	+37%	+$6.13M	0.02%	755
2019 Q4	$16.7M	Buy	355,090 +310,704	+700%	+$13.7M	0.01%	1131
2019 Q3	$1.05M	Buy	44,386 +8,293	+23%	+$246K	﹤0.01%	2977
2019 Q2	$1.08M	Sell	36,093 -18,634	-34%	-$427K	﹤0.01%	2885
2019 Q1	$1.23M	Buy	+54,727	New	+$1.18M	﹤0.01%	2727
2018 Q2	–	Sell	-294,681	Closed	-$1.56M	–	4234
2018 Q1	$1.56M	Buy	+294,681	New	+$2.11M	﹤0.01%	2619
2017 Q4	–	Sell	-10,151	Closed	-$148K	–	4305
2017 Q3	$148K	Buy	+10,151	New	+$153K	﹤0.01%	4009

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Credit Suisse's RARX Position: Q2 2020 in Review

Credit Suisse sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 486,872 shares — an estimated $23.4M sold.

Credit Suisse first reported a position in RARX in Q3 2017 and held it in 7 quarters. The position peaked at $23.4M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

Credit Suisse reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Credit Suisse sold 486,872 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $23.4M.
Credit Suisse first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 7 quarters.
Credit Suisse's Ra Pharmaceuticals, Inc. Common Stock position peaked at $23.4M in Q1 2020.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Credit Suisse's 13F filing for Q2 2020, filed 12 Aug 2020.